Background and purpose: Natalizumab (NTZ) is a highly effective treatment for relapsing-remitting multiple sclerosis (MS), but its withdrawal is often followed by disease reactivation or rebound, even if other disease-modifying treatments (DMTs) are administered. In this study, for the first time, the safety and efficacy of autologous hematopoietic stem-cell transplantation (aHSCT) performed following NTZ discontinuation were retrospectively compared with conventional DMTs. Methods: Patients with relapsing-remitting MS treated with NTZ who discontinued the drug after at least six administrations and with at least 6 months of follow-up were included. Patients underwent aHSCT after a minimum of 6 months following NTZ withdrawal, receiving meanwhile cyclophosphamide or corticosteroids, or other DMTs approved for MS (control group) after an adequate wash-out period. Both hematological and neurological follow-up were assessed according to standard policies. Results: A total of 52 patients were included, 11 who received aHSCT and 41 who received DMTs. Baseline clinical and demographic characteristics were similar between the two groups. No fatality or life-threatening complications, including progressive multifocal leukoencephalopathy, were observed. At 3 years following NTZ discontinuation, no evidence of disease activity was reported in 54.5% of the patients in the aHSCT group compared with 11.5% of those in the DMT group (P = 0.0212). Disease reactivation in the patients with aHSCT was observed only during wash-out/bridging therapy and 100% of the cases were free from disease activity after aHSCT. Conclusions: These data suggest that an aggressive therapy should be established after NTZ with the shortest possible wash-out period. aHSCT after 6 months from NTZ withdrawal appears to be safe.
Introduction
In the last few decades, several disease-modifying treatments (DMTs) with different efficacy and safety profiles have been approved for the treatment of multiple sclerosis (MS). Clinical trials assessing the efficacy of DMTs usually attempt to achieve ambitious treatment goals, such as 'no evidence of disease activity' (NEDA). The evaluation of this outcome is based on the combined use of clinical and radiological parameters [1] . Natalizumab (NTZ) is an effective and widely used DMT for relapsing-remitting MS (RRMS), which is frequently discontinued in clinical practice in patients at high risk of developing progressive multifocal leukoencephalopathy (PML) [2] . Since worldwide approval of this medication, 766 patients have developed confirmed PML linked to NTZ, with a global risk estimate of 4.16 cases per 1000 patients exposed (update March 2018) [3, 4] . In addition, clinical and/or radiological disease recurrence is frequently reported after NTZ withdrawal, sometimes more aggressive than in the pre-treatment period, which could determine irreversible disability accrual [5] [6] [7] . At present, there is no consensus about the best treatment strategy to be used in order to prevent such a phenomenon [8] . Recently published studies report a variable efficacy of approved DMTs in preventing disease reactivation [9] , but no data are available on autologous hematopoietic stem-cell transplantation (aHSCT), a procedure used for the treatment of hematological diseases, which is not supportable as a therapy for the general MS population but designated as a clinical option for treatment of patients with aggressive MS unresponsive to the conventional and approved DMTs [10] . The aim of aHSCT is to restore a new immune tolerance through an intense chemotherapy, followed by the infusion of autologous hematopoietic stem cells previously collected from the patient [11, 12] . Since the first procedure was performed in patients with MS in 1995 [13] , almost 800 patients with MS in Europe have received aHSCT with encouraging results [14, 15] .
Materials and methods

Study design
This single-center retrospective cohort study aimed to evaluate the safety profile and efficacy of aHSCT performed in patients with RRMS following NTZ withdrawal and receiving meanwhile a bridging therapy.
Patient selection
Patients affected by RRMS according to the Poser and Mc Donald criteria and who discontinued NTZ after receiving at least six infusions at the Multiple Sclerosis Referral Center for Tuscany, Careggi University Hospital, Florence from January 2010 to June 2016 were consecutively included. Patients who showed clinical and/ or radiological disease activity during NTZ treatment or who had received NTZ as first DMT due to highly active disease were offered aHSCT, according to the inclusion criteria of the approved local experimental protocol for aHSCT in MS. Patients who refused transplant or had contraindications to the procedure and those who showed mild or no disease activity received conventional treatments (control group).
Disease-modifying treatments received in the control group
For each patient of the DMT group, a first-line (interferons, glatiramer acetate, dimethylfumarate) or second-line DMT [fingolimod, alemtuzumab, rituximab, cyclophosphamide (Cy), mitoxantrone] was chosen by the treating neurologist according to the patient's disease activity, comorbidities and tolerability. Wash-out periods varied according to the DMT adopted and the clinical judgment of the treating neurologist.
Transplant procedure
The patients received aHSCT at the Cellular Therapies and Transplant Unit of the hospital after a minimum of 6 months from last NTZ administration, pre-defined according to the local transplant protocol. In this interval period a bridging therapy was established, consisting of monthly intravenous administrations of Cy (0.75 g/m 2 ) or corticosteroid methylprednisolone (1 g/day for 3 days). All of the patients were then treated with the same protocol. Peripheral hematopoietic stem cells were mobilized by the association of Cy (4 g/m 2 ) in two doses on the same day followed by daily granulocyte colony-stimulating factor starting at day +5 (5-12 lg/kg per day), until completion of the harvest. The conditioning regimen used was BEAM/ATG (carmustine 300 mg/m 2 at day À6, cytosine-arabinoside 200 mg/m 2 and etoposide 200 mg/m 2 from day À5 to day À2, melphalan 140 mg/m 2 at day À1; rabbit antithymocyte globulin at a dose of 3.75 mg/kg/day on day +1 and +2) an intermediate-intensity conditioning regimen according to the European Society for Blood and Marrow Transplantation classification. All patients included in the transplant program gave informed consent according to the standard policy of the recruiting center and the protocol was approved by the local ethics committee.
Clinical examinations and outcomes
Patients in the aHSCT group had a standardized hematological and neurological evaluation at baseline. After the procedure, they had regular blood tests in order to assess engraftment and to detect viral reactivations or any other adverse events. All patients had clinical examinations with an assessment of disability [Expanded Disability Status Scale (EDSS)] at 6 and 12 months and then at least yearly after the last NTZ infusion. Brain magnetic resonance imaging was performed at baseline, at 6 and 12 months and then every year.
The outcomes of interest were safety, assessed in terms of severe adverse events and transplant-related mortality, and efficacy of aHSCT. The efficacy was evaluated by comparing the following outcomes between the aHSCT and DMT groups: NEDA-3 (absence of relapses, disability progression and new MRI lesions) survival at 3 years after NTZ withdrawal; annualized relapse rate (ARR) during NTZ and following its discontinuation; and proportion of patients showing EDSS score change at 3 years of follow-up.
Wash-out period was defined as the period between the last NTZ administration and the start of the first DMT for patients in the DMT group or between the last NTZ administration and chemotherapy of aHSCT for those in the aHSCT group. See Appendix S1 for the other definitions and statistical methods.
Results
Patient characteristics
Between January 2010 and June 2016, NTZ therapy was discontinued in 52 patients with RRMS (40 females and 12 males) after a median of 24 [interquartile range (IQR), 23-32.5] infusions ( Fig. 1 ). A total of 11 patients underwent aHSCT, whereas the remaining 41 were treated with approved DMTs. Seven out of 41 patients included in the latter group were offered aHSCT but refused or were unable to undergo the procedure. NTZ withdrawal was mainly due to PML risk for John Cunningham virus (JCV) carrier status (72.7% of the patients in the aHSCT group and 85.4% of the patients in the DMT group). At NTZ discontinuation, clinical and demographical characteristics of patients were similar in the two groups (Table 1) .
Treatment strategies
Autologous hematopoietic stem-cell transplantation was performed after a median of 8 (IQR, 6-15) months from the last NTZ infusion. In this interval period, all of the patients received a bridging therapy (seven patients with Cy and four with corticosteroid methylprednisolone) for a median of 4 (IQR, 2-5) months, starting after at least 2 months following NTZ withdrawal. Patients in the control group were treated with approved DMTs after a median wash-out period of 4 (IQR, 2-6) months. A total of 28/41 patients (68.3%) received a second-line treatment and 13/41 (31.7%) received a first-line treatment. Details about the DMTs adopted are shown in Table S1 .
Safety/adverse events
No fatalities or life-threatening complications, including PML, were reported in either group. The number of viral reactivations detected after aHSCT was consistent with other transplant studies and they were all treated without hospitalization and sequelae. Four infective pneumonias were reported as occurring in three patients of the transplant group. All of the events occurred within 1 year from transplant, three out of four within 6 months. Three out of four cases required hospitalization and were thus considered severe adverse events. All of the patients recovered completely after medical therapy. One patient in the aHSCT group (9%) was diagnosed with autoimmune thyroiditis at month 4 after transplant (Fig. 2 ).
NEDA-3 comparison
At 3 years of follow-up (Fig. 3a) , NEDA-3 was 54.5% in the aHSCT group and 11.5% in the DMT group (P = 0.0212). During the wash-out period (Fig. 3b) , NEDA-3 survival was 39% for the aHSCT group and 42% for the DMT group (P = 0.6083). No clinical or radiological disease reactivations were observed following aHSCT (Fig. 3c) , whereas only 11% of the patients in the DMT group showed NEDA-3 survival after DMT initiation (P < 0.0001). A total of 10 patients in the DMT group showed high disease activity despite DMT treatment and ultimately underwent aHSCT (seven patients) or alemtuzumab (three patients) as 'rescue therapy'.
Clinical relapses
During NTZ treatment, ARR was 0.28 for the aHSCT group and 0.21 for the DMT group. In the wash-out period, ARR increased for both groups (1.29 and 1.15, respectively; P = 0.5356). From aHSCT/DMT administration to month 36 after the last NTZ infusion, ARR was significantly lower in the patients with aHSCT compared with the patients with DMT (0.00 vs. 0.67, P < 0.0001) (Fig. 4) .
Disability worsening
Median EDSS scores at the last NTZ administration and at month 36 of follow-up were 3.25 (IQR, 2.0-4.5) and 3.75 (IQR, 2.0-4.5) for the patients in the aHSCT group and 2.0 (IQR, 1.5-4.5) and 4.25 (IQR, 1.5-6.0) for those in the DMT group (Fig. S1 ). At 3 years of follow-up, 44.4% of the patients in the aHSCT group showed confirmed improvement of EDSS score compared with 6.1% of the patients in the DMT group (P = 0.013) (Fig. 5) . None of the patients in the aHSCT group showed conversion to a secondary progressive course following aHSCT, but four out of 41 patients (P = 0.566) in the DMT group did show conversion.
Discussion
There is currently a lack of consensus about the best treatment strategy to be used after NTZ cessation. According to published data, fingolimod showed a positive effect in controlling disease activity after NTZ, although at least 50% of treated patients experienced clinical disease activity [16] ; better results can be achieved if the treatment is administered with wash-out periods shorter than 3 months, despite greater safety issues [17] . In a recently published cohort of 256 patients who were treated with fingolimod or rituximab after NTZ withdrawal due to PML risk, rituximab showed notable efficacy in halting clinical and radiological disease reactivation at 1.5 years of follow-up [18] . In another observational study [19] , 16 JCV-positive patients were treated with alemtuzumab following NTZ discontinuation. All patients showed disease stabilization, although with a short follow-up duration, and no cases of PML were reported. In the absence of any published evidence, we considered it adequately safe to perform aHSCT adopting a minimum interval period of 6 months from the last NTZ infusion. In order to prevent disease reactivation in this period, patients were treated with a bridging therapy (monthly intravenous pulses of Cy or corticosteroid methylprednisolone), starting after at least 2 months of wash-out. Cy was chosen because it showed an acceptable and rapid-acting disease activity control in a previously published study [20] and both drugs appeared to be adequately safe even if performed shortly before the transplant.
To our knowledge, this is the first cohort of patients treated with aHSCT following NTZ cessation. The safety profile of the procedure seems to be acceptable: despite JCV positivity in 73% of patients treated, no cases of PML were reported, even if the wash-out period adopted was short compared with the high grade of immunosuppression induced by aHSCT. A higher incidence of infection-related adverse events was observed in patients transplanted after NTZ compared with those who received other DMTs (20% vs. 5% in our cohort, unpublished data). These preliminary data, although derived from small samples, suggest the need for careful monitoring of the clinical outcome in the year following aHSCT in this subgroup of patients.
However, the outcome of the procedure was not impaired. In the aHSCT group, the bridging therapy was not adequate to control disease activity and almost half of the patients experienced a disease reactivation before transplant. In the present study, 89% The divergence between the two groups is observed starting from month 8 following the last NTZ infusion. NEDA-3 failure during the wash-out period was similar between the two groups and all of the disease reactivations reported in the patients with aHSCT were observed during the washout/bridging therapy. Almost 90% of the patients in the DMT group showed NEDA-3 failure despite the initiation of DMTs, whereas there were no NEDA-3 failures following aHSCT, performed after a median of 8 (interquartile range, 6-15) months. Black line, aHSCT; gray line, DMT.
of the patients receiving DMTs failed the NEDA-3 endpoint, whereas none of the 11 patients showed any signs of disease reactivation after the transplant, thus achieving a NEDA-3 of 100% at a median of 33 (IQR, 19-39) months of follow-up after aHSCT. Data regarding the efficacy of the transplant are aligned with those recently emerging from the literature with regard to populations of patients with highly active RRMS [21, 22] . Moreover, a significantly higher percentage of patients in the aHSCT group showed a long-term disability improvement compared with those in the DMT group (P = 0.013). This result may be related to the mechanism of action of the transplant that induces an intense and rapid suppression of central nervous system inflammation. Our study has several limitations. Patients who underwent aHSCT were selected for more aggressive disease course and this could bias against the aHSCT arm. Moreover, a remarkable percentage of patients in the DMT group (31.7%) de-escalated therapy and therefore it is not surprising that disease control was worse than before. Indeed, de-escalation was reserved Figure 4 Annualized relapse rate (ARR) during natalizumab (NTZ) therapy, wash-out period and from autologous hematopoietic stem-cell transplantation (aHSCT)/initiation of disease-modifying treatments (DMTs) to month 36 of follow-up after NTZ discontinuation in the aHSCT and DMT groups. The ARR increased after NTZ cessation in both groups. Following the administration of treatment, ARR remained higher than during NTZ therapy in the DMT group, whereas it dropped to zero after transplant in the patients with aHSCT. Significant P-values are given in the figure. , aHSCT; ■, DMT. Figure 5 Frequency of patients showing Expanded Disability Status Scale (EDSS) score changes during natalizumab (NTZ) treatment and at year 3 of follow-up. The proportion of patients showing disability stabilization or improvement during follow-up was significantly higher in the autologous hematopoietic stem-cell transplantation (aHSCT) group compared with the disease-modifying treatment (DMT) group. *P = 0.013. , EDSS improvement; , EDSS stabilization; ■, EDSS deterioration.
for patients who could not receive an aggressive therapy due to safety issues or tolerability.
In conclusion, in the absence of literature evidence, our results suggest that performing aHSCT with an interval period of almost 6 months from NTZ withdrawal appears to be adequately safe, providing that careful monitoring is carried out during the first year after transplant. aHSCT was able to prevent potentially disabling disease reactivations following NTZ discontinuation. These preliminary data also suggest that an aggressive approach therapy should be adopted after NTZ with the shortest wash-out period as allowed by safety concerns (e.g. 4-6 months before the transplant), the intensity of the treatment appearing to be the most relevant factor in inducing disease remission.
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